This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This ADRA2C antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 354-382 amino acids from the C-terminal region of human ADRA2C.
ADRA2C
Reactivity: Human
WB, ICC, IF
Host: Mouse
Monoclonal
S330A-80
Atto 594
Application Notes
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50
Restrictions
For Research Use only
Format
Liquid
Concentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
ADRA2C
(Adrenergic, alpha-2C-, Receptor (ADRA2C))
Alternative Name
ADRA2C
Background
Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. They include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. The mouse studies revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons. The alpha2A subtype inhibited transmitter release at high stimulation frequencies, whereas the alpha2C subtype modulated neurotransmission at lower levels of nerve activity. This gene encodes the alpha2C subtype, which contains no introns in either its coding or untranslated sequences.